Cargando…
Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Autores principales: | Bolomsky, Arnold, Vogler, Meike, Köse, Murat Cem, Heckman, Caroline A., Ehx, Grégory, Ludwig, Heinz, Caers, Jo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888147/ https://www.ncbi.nlm.nih.gov/pubmed/33596924 http://dx.doi.org/10.1186/s13045-021-01043-z |
Ejemplares similares
-
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
por: Bolomsky, Arnold, et al.
Publicado: (2020) -
Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021) -
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021) -
Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells
por: Ritacco, Caroline, et al.
Publicado: (2023) -
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2018)